Compounding: Hamburg, Dems Look To Shift Spotlight Away From FDA As Hearing Looms
This article was originally published in The Pink Sheet Daily
After a House subcommittee announces hearing focused on whether FDA could have prevented the meningitis outbreak at the New England Compounding Center, FDA commissioner and subcommittee Democrats write about apparent outside efforts to sidestep and delay compounder inspections.
You may also be interested in...
Iowa has contracted with a national pharmacy group to inspect facilities outside its borders. Although the program could serve as a potential model for a nationwide plan, it also could bring several problems.
Agency releases 483 forms from a post-crises inspection push; the effort may help FDA illustrate its inspection capabilities to Congress and states and indicate the agency’s oversight plans under the new authority it has proposed.
A single-arm trial using a biomarker and animal model could be enough for an accelerated approval, especially in a pediatric rare disease where randomization and placebo controls may not be feasible, the CBER director said.